Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pilots Between NHS And Pharma Finally Take Off

The majority of pharmaceutical companies in the UK work closely with the NHS and In Vivo spoke to one of them – Janssen – to see how successful industry, health care providers and payers have been in breaking out of their silos and collaborating.

United Kingdom Commercial Market Access

Cross-Country Collaborations, Business As Usual?

Pharmaceutical companies cannot afford to ignore the growing number of cross-country collaborations springing up in Europe aimed at securing more affordable medicines through actions such as jointly negotiated pricing deals. In Vivo looks at the factors that may influence the rise or fall of these collaborations and at how they may eventually make companies rethink the way they do business.

Market Access Outlook 2019 Pricing Strategies

Set, Ready, Afford: China Rushes To Access Innovation Amid New Drug Dash

2018 is set to break the record for new drug approvals in China, which have included some immuno-oncology and powerful antiviral therapies. Providing access to these high-priced medicines to more patients in the populous country was high on the minds of several multinationals during a recent conference in Shanghai.

China Commercial Market Access

No, It's Not Just Out-Of-Pocket Costs That Are A Problem, John Arnold Tells Pharma

The billionaire philanthropist and industry agitator took the stage at the Forbes Healthcare Summit to discuss why his foundation is focused on fixing drug pricing and supporting organizations like ICER and Patients for Affordable Drugs.

Pricing Strategies Policy Government Payers

Cell And Gene Therapies Test New Waters In Pricing And Reimbursement

With the first few cell and gene therapies launched in the US, the challenge of pricing and reimbursement – and the opportunity to set the standards in this area – was a repeated theme at the Alliance for Regenerative Medicine's Cell and Gene Meeting on the Mesa.

Reimbursement Regenerative Medicine Launches
UsernamePublicRestriction

Register